



**Pharmacy and Therapeutics Committee Decisions  
November 11, 2016**

Type of Review	Drug/Therapeutic Class	P&T Decision								
New Medication	<p><b>Venclexta™ (venetoclax oral tablets – AbbVie/Genentech)</b></p> <table border="1" data-bbox="396 792 1304 1089"> <thead> <tr> <th data-bbox="396 792 1052 899">Drug Name</th> <th data-bbox="1052 792 1304 899">Current Formulary Status</th> </tr> </thead> <tbody> <tr> <td data-bbox="396 899 1052 976">Imbruvica® (ibrutinib oral capsules – AbbVie/Pharmacyclics, Janssen Biotech, Inc.)</td> <td data-bbox="1052 899 1304 976">F [PA]</td> </tr> <tr> <td data-bbox="396 976 1052 1052">Venclexta™ (venetoclax oral tablets – AbbVie/Genentech)</td> <td data-bbox="1052 976 1304 1052">NF</td> </tr> <tr> <td data-bbox="396 1052 1052 1089"></td> <td data-bbox="1052 1052 1304 1089"></td> </tr> </tbody> </table>	Drug Name	Current Formulary Status	Imbruvica® (ibrutinib oral capsules – AbbVie/Pharmacyclics, Janssen Biotech, Inc.)	F [PA]	Venclexta™ (venetoclax oral tablets – AbbVie/Genentech)	NF			<p><b>Recommendation</b></p> <p>Add Venclexta to formulary with prior authorization criteria.</p> <p><b>Decision: Approved</b></p>
Drug Name	Current Formulary Status									
Imbruvica® (ibrutinib oral capsules – AbbVie/Pharmacyclics, Janssen Biotech, Inc.)	F [PA]									
Venclexta™ (venetoclax oral tablets – AbbVie/Genentech)	NF									
	<p><b>Cabometryx™ (cabozantinib oral tablets – Exelixis, Inc.)</b></p> <table border="1" data-bbox="396 1166 1287 1427"> <thead> <tr> <th data-bbox="396 1166 999 1242">Drug Name</th> <th data-bbox="999 1166 1287 1242">Current Formulary Status</th> </tr> </thead> <tbody> <tr> <td data-bbox="396 1242 999 1318">Afinitor® (everolimus oral tablets – Norvartis Pharmaceutical Co.)</td> <td data-bbox="999 1242 1287 1318">F [PA]</td> </tr> <tr> <td data-bbox="396 1318 999 1395">Cabometryx™ (cabozantinib oral tablets – Exelixis, Inc.)</td> <td data-bbox="999 1318 1287 1395">NF [PA]</td> </tr> <tr> <td data-bbox="396 1395 999 1427">Inlyta® (axitinib oral tablets – Pfizer Inc.)</td> <td data-bbox="999 1395 1287 1427">F [PA]</td> </tr> </tbody> </table>	Drug Name	Current Formulary Status	Afinitor® (everolimus oral tablets – Norvartis Pharmaceutical Co.)	F [PA]	Cabometryx™ (cabozantinib oral tablets – Exelixis, Inc.)	NF [PA]	Inlyta® (axitinib oral tablets – Pfizer Inc.)	F [PA]	<p><b>Recommendation</b></p> <ol style="list-style-type: none"> <li>1. Add Cabometryx to formulary with prior authorization criteria.</li> <li>2. Add Afinitor prior authorization criteria for</li> </ol>
Drug Name	Current Formulary Status									
Afinitor® (everolimus oral tablets – Norvartis Pharmaceutical Co.)	F [PA]									
Cabometryx™ (cabozantinib oral tablets – Exelixis, Inc.)	NF [PA]									
Inlyta® (axitinib oral tablets – Pfizer Inc.)	F [PA]									

	<table border="1"> <tr> <td data-bbox="382 240 999 315"><b>Sutent<sup>®</sup></b> (sunitinib oral tablets – Pfizer Inc.)</td> <td data-bbox="999 240 1287 315"><b>F [PA]</b></td> </tr> <tr> <td data-bbox="382 315 999 389"><b>Votrient<sup>®</sup></b> (pazopanib oral tablets – Novartis Pharmaceutical Co.)</td> <td data-bbox="999 315 1287 389"><b>F [PA]</b></td> </tr> <tr> <td data-bbox="382 389 999 464"><b>Opdivo<sup>™</sup></b> (nivolumab IV– Bristol-Myers Squibb)</td> <td data-bbox="999 389 1287 464"><b>Medical F[PA]</b></td> </tr> </table>	<b>Sutent<sup>®</sup></b> (sunitinib oral tablets – Pfizer Inc.)	<b>F [PA]</b>	<b>Votrient<sup>®</sup></b> (pazopanib oral tablets – Novartis Pharmaceutical Co.)	<b>F [PA]</b>	<b>Opdivo<sup>™</sup></b> (nivolumab IV– Bristol-Myers Squibb)	<b>Medical F[PA]</b>		<p>subsequent treatment of RCC to allow coverage after trial and failure of Cabometyx or Opdivo.</p> <p><b>3. Retain the current formulary status for the remaining drugs.</b></p> <p>Decision: Approved</p>		
<b>Sutent<sup>®</sup></b> (sunitinib oral tablets – Pfizer Inc.)	<b>F [PA]</b>										
<b>Votrient<sup>®</sup></b> (pazopanib oral tablets – Novartis Pharmaceutical Co.)	<b>F [PA]</b>										
<b>Opdivo<sup>™</sup></b> (nivolumab IV– Bristol-Myers Squibb)	<b>Medical F[PA]</b>										
	<p><b>Ocaliva<sup>™</sup></b> (obeticholic acid tablets –Intercept Pharmaceuticals)</p> <table border="1"> <thead> <tr> <th data-bbox="382 834 999 909">Drug Name</th> <th data-bbox="999 834 1287 909">Current Formulary Status</th> </tr> </thead> <tbody> <tr> <td data-bbox="382 909 999 984"><b>Ocaliva<sup>™</sup></b> (obeticholic acid tablets – Intercept Pharmaceuticals)</td> <td data-bbox="999 909 1287 984"><b>NF</b></td> </tr> <tr> <td data-bbox="382 984 999 1058">ursodeoxycholic acid 300mg capsules (generics)</td> <td data-bbox="999 984 1287 1058"><b>F</b></td> </tr> <tr> <td data-bbox="382 1058 999 1133">ursodeoxycholic acid 250mg and 500mg tablets (generics)</td> <td data-bbox="999 1058 1287 1133"><b>NF</b></td> </tr> </tbody> </table>	Drug Name	Current Formulary Status	<b>Ocaliva<sup>™</sup></b> (obeticholic acid tablets – Intercept Pharmaceuticals)	<b>NF</b>	ursodeoxycholic acid 300mg capsules (generics)	<b>F</b>	ursodeoxycholic acid 250mg and 500mg tablets (generics)	<b>NF</b>		<p>Recommendation</p> <p><b>1. Retain Ocaliva as non-formulary.</b></p> <p>Decision: Approved</p>
Drug Name	Current Formulary Status										
<b>Ocaliva<sup>™</sup></b> (obeticholic acid tablets – Intercept Pharmaceuticals)	<b>NF</b>										
ursodeoxycholic acid 300mg capsules (generics)	<b>F</b>										
ursodeoxycholic acid 250mg and 500mg tablets (generics)	<b>NF</b>										

	<table border="1"> <thead> <tr> <th>Drug Name</th> <th>Current Formulary Status</th> </tr> </thead> <tbody> <tr> <td>clozapine tablets (generics)</td> <td>F [PA]</td> </tr> <tr> <td>Nuplazid™ (pimavanserin tablets –Acadia Pharmaceuticals Inc)</td> <td>NF</td> </tr> <tr> <td>quetiapine tablets (generics)</td> <td>F</td> </tr> <tr> <td>quetiapine tablets (Seroquel® – AztraZeneca Pharmaceuticals)</td> <td>NF</td> </tr> <tr> <td>quetiapine tablets (Seroquel XR® – AztraZeneca Pharmaceuticals)</td> <td>F</td> </tr> </tbody> </table>	Drug Name	Current Formulary Status	clozapine tablets (generics)	F [PA]	Nuplazid™ (pimavanserin tablets –Acadia Pharmaceuticals Inc)	NF	quetiapine tablets (generics)	F	quetiapine tablets (Seroquel® – AztraZeneca Pharmaceuticals)	NF	quetiapine tablets (Seroquel XR® – AztraZeneca Pharmaceuticals)	F	<p><b>Recommendation</b></p> <ol style="list-style-type: none"> <li>1. Retain Nuplazid as non-formulary.</li> <li>2. Retain formulary status for all other medications.</li> </ol> <p><b>Decision:</b> Approved</p>		
Drug Name	Current Formulary Status															
clozapine tablets (generics)	F [PA]															
Nuplazid™ (pimavanserin tablets –Acadia Pharmaceuticals Inc)	NF															
quetiapine tablets (generics)	F															
quetiapine tablets (Seroquel® – AztraZeneca Pharmaceuticals)	NF															
quetiapine tablets (Seroquel XR® – AztraZeneca Pharmaceuticals)	F															
<b>Therapeutic Summary Class Review</b>																
	<p><b>Phosphate Binders</b></p> <table border="1"> <thead> <tr> <th>Drug Name</th> <th>Formulary Status</th> </tr> </thead> <tbody> <tr> <td>Auryxia™ (ferric citrate tablets – Keryx Pharmaceuticals)</td> <td>NF</td> </tr> <tr> <td>Fosrenol® (lanthanum carbonate oral powder – Shire)</td> <td>NF</td> </tr> <tr> <td>Fosrenol® (lanthanum carbonate chewable tablets– Shire)</td> <td>F</td> </tr> <tr> <td>sevelamer carbonate (generics) - DISCONTINUED</td> <td>F</td> </tr> <tr> <td>Renagel® (sevelamer hydrochloride tablets – Genzyme)</td> <td>F</td> </tr> <tr> <td>Renvela® (sevelamer for oral suspension –</td> <td>F</td> </tr> </tbody> </table>	Drug Name	Formulary Status	Auryxia™ (ferric citrate tablets – Keryx Pharmaceuticals)	NF	Fosrenol® (lanthanum carbonate oral powder – Shire)	NF	Fosrenol® (lanthanum carbonate chewable tablets– Shire)	F	sevelamer carbonate (generics) - DISCONTINUED	F	Renagel® (sevelamer hydrochloride tablets – Genzyme)	F	Renvela® (sevelamer for oral suspension –	F	<p><b>Recommendation</b></p> <ol style="list-style-type: none"> <li>1. Keep the current formulary status for the remaining drugs.</li> </ol> <p><b>Decision:</b> Approved</p>
Drug Name	Formulary Status															
Auryxia™ (ferric citrate tablets – Keryx Pharmaceuticals)	NF															
Fosrenol® (lanthanum carbonate oral powder – Shire)	NF															
Fosrenol® (lanthanum carbonate chewable tablets– Shire)	F															
sevelamer carbonate (generics) - DISCONTINUED	F															
Renagel® (sevelamer hydrochloride tablets – Genzyme)	F															
Renvela® (sevelamer for oral suspension –	F															

	<b>Genzyme)</b>		
	<b>Renvela<sup>®</sup> (sevelamer carbonate tablets– Genzyme)</b>	<b>F</b>	
	<b>Velphoro<sup>®</sup> (sucroferric oxyhydroxide chewable tablet – Fresenius Medical Care)</b>	<b>NF</b>	
	<b>Inflammatory Bowel Therapy – Mesalamines</b>		<b>Recommendation</b>
	<b>Drug Name</b>	<b>Current Formulary Status</b>	
	<b>balsalazide tablets (generic)</b>	<b>F [PA]</b>	
	<b>mesalamine extended release capsule (Apriso<sup>®</sup> – Meda)</b>	<b>NF</b>	<b>1. Add Apriso<sup>®</sup> to formulary.</b>
	<b>mesalamine enteric-coated, delayed-release tablet (Asacol<sup>®</sup> – Warner Chilcott)</b>	<b>F</b>	<b>2.Add Step Therapy to olsalazine (Dipentum<sup>®</sup>)</b>
	<b>mesalamine delayed-release tablet (Lialda<sup>®</sup> – Shire-US)</b>	<b>NF</b>	<b>3. Retain the current formulary status for the remaining drugs.</b>
	<b>mesalamine controlled-release capsule (Pentasa<sup>®</sup> – Shire-US)</b>	<b>NF</b>	<b>Decision: Approved</b>
	<b>mesalamine enteric-coated, delayed-release capsule (Delzicol<sup>™</sup> – Warner Chilcott)</b>	<b>NF</b>	
	<b>mesalamine rectal enema (generic)</b>	<b>F</b>	
	<b>mesalamine rectal suppository (Canasa<sup>®</sup> – Allergan)</b>	<b>F</b>	
	<b>olsalazine capsule (Dipentum<sup>®</sup> – Alaven Pharmaceuticals)</b>	<b>F</b>	
	<b>sulfasalazine immediate release, delayed release tablet (generic)</b>	<b>F</b>	

	<p><b>Inflammatory Conditions, Inflammatory Bowel – Biologics</b></p> <table border="1" data-bbox="396 310 1289 1065"> <thead> <tr> <th data-bbox="396 310 1008 383">Drug Name</th> <th data-bbox="1008 310 1289 383">Current Formulary Status</th> </tr> </thead> <tbody> <tr> <td data-bbox="396 383 1008 456">Cimzia<sup>®</sup> (certolizumab pegol for SC injection – UCB, Inc.)</td> <td data-bbox="1008 383 1289 456">NF</td> </tr> <tr> <td data-bbox="396 456 1008 529">Humira<sup>®</sup> (adalimumab for SC injection – AbbVie)</td> <td data-bbox="1008 456 1289 529">F [PA]</td> </tr> <tr> <td data-bbox="396 529 1008 602">Humira<sup>®</sup> Pen (adalimumab for SC injection – AbbVie)</td> <td data-bbox="1008 529 1289 602">F [PA]</td> </tr> <tr> <td data-bbox="396 602 1008 675">Humira<sup>®</sup> Pen Crohn’s (adalimumab for SC injection – AbbVie)</td> <td data-bbox="1008 602 1289 675">F [PA]</td> </tr> <tr> <td data-bbox="396 675 1008 748">Humira<sup>®</sup> Pen Psoriasis (adalimumab for SC injection – AbbVie)</td> <td data-bbox="1008 675 1289 748">NF</td> </tr> <tr> <td data-bbox="396 748 1008 821">Simponi<sup>®</sup> (golimumab for SC injection – Janssen Biotech)</td> <td data-bbox="1008 748 1289 821">NF</td> </tr> <tr> <td data-bbox="396 821 1008 894">Remicade<sup>®</sup> (infliximab IV injection – Janssen Biotech)</td> <td data-bbox="1008 821 1289 894">Medical</td> </tr> <tr> <td data-bbox="396 894 1008 967">Entyvio<sup>®</sup> (vedolizumab for IV injection – Takeda)</td> <td data-bbox="1008 894 1289 967">Medical</td> </tr> <tr> <td data-bbox="396 967 1008 1065">Tysabri<sup>®</sup> (natalizumab IV infusion – Biogen Idec)</td> <td data-bbox="1008 967 1289 1065">Medical</td> </tr> </tbody> </table>	Drug Name	Current Formulary Status	Cimzia <sup>®</sup> (certolizumab pegol for SC injection – UCB, Inc.)	NF	Humira <sup>®</sup> (adalimumab for SC injection – AbbVie)	F [PA]	Humira <sup>®</sup> Pen (adalimumab for SC injection – AbbVie)	F [PA]	Humira <sup>®</sup> Pen Crohn’s (adalimumab for SC injection – AbbVie)	F [PA]	Humira <sup>®</sup> Pen Psoriasis (adalimumab for SC injection – AbbVie)	NF	Simponi <sup>®</sup> (golimumab for SC injection – Janssen Biotech)	NF	Remicade <sup>®</sup> (infliximab IV injection – Janssen Biotech)	Medical	Entyvio <sup>®</sup> (vedolizumab for IV injection – Takeda)	Medical	Tysabri <sup>®</sup> (natalizumab IV infusion – Biogen Idec)	Medical	<p><b>Recommendation</b></p> <p>1. Move Humira<sup>®</sup> Pen Psoriasis (adalimumab SC for injection) to formulary status with PA.</p> <p>2. Retain all other medications in current formulary status.</p> <p><b>Decision:</b> Approved</p>
Drug Name	Current Formulary Status																					
Cimzia <sup>®</sup> (certolizumab pegol for SC injection – UCB, Inc.)	NF																					
Humira <sup>®</sup> (adalimumab for SC injection – AbbVie)	F [PA]																					
Humira <sup>®</sup> Pen (adalimumab for SC injection – AbbVie)	F [PA]																					
Humira <sup>®</sup> Pen Crohn’s (adalimumab for SC injection – AbbVie)	F [PA]																					
Humira <sup>®</sup> Pen Psoriasis (adalimumab for SC injection – AbbVie)	NF																					
Simponi <sup>®</sup> (golimumab for SC injection – Janssen Biotech)	NF																					
Remicade <sup>®</sup> (infliximab IV injection – Janssen Biotech)	Medical																					
Entyvio <sup>®</sup> (vedolizumab for IV injection – Takeda)	Medical																					
Tysabri <sup>®</sup> (natalizumab IV infusion – Biogen Idec)	Medical																					
	<p><b>Corticosteroids (Rectal) for Ulcerative Colitis</b></p> <table border="1" data-bbox="396 1313 1320 1377"> <thead> <tr> <th data-bbox="396 1313 1064 1377">Drug Name</th> <th data-bbox="1064 1313 1320 1377">Current Formulary Status</th> </tr> </thead> <tbody> <tr> <td data-bbox="396 1377 1064 1377"></td> <td data-bbox="1064 1377 1320 1377"></td> </tr> </tbody> </table>	Drug Name	Current Formulary Status			<p><b>Recommendation</b></p> <p><b>Move Colocort<sup>®</sup></b></p>																
Drug Name	Current Formulary Status																					

	<table border="1"> <tr> <td>budesonide rectal foam (Uceris® – Salix Pharmaceuticals)</td> <td>NF</td> </tr> <tr> <td>hydrocortisone retention enema (Colocort® – Dynamic Pharmaceuticals)</td> <td>NF</td> </tr> <tr> <td>hydrocortisone retention enema (generics)</td> <td>F</td> </tr> <tr> <td>hydrocortisone 2.5% cream (generics)</td> <td>NF</td> </tr> <tr> <td>hydrocortisone 2.5% cream (Procto-Med HC – Leading Pharmaceuticals)</td> <td>NF</td> </tr> <tr> <td>hydrocortisone 1% cream (Procto-Pak – Rising Pharmaceuticals)</td> <td>F</td> </tr> <tr> <td>hydrocortisone 2.5% cream (Proctosol HC – Taro Pharmaceuticals)</td> <td>NF</td> </tr> <tr> <td>hydrocortisone 2.5% cream (Proctozone HC – Rising Pharmaceuticals)</td> <td>F</td> </tr> <tr> <td>hydrocortisone 2.5% cream (Anusol-HC® – Salix Pharmaceuticals)</td> <td>NF</td> </tr> <tr> <td>hydrocortisone foam (Cortifoam® – Meda Pharmaceuticals)</td> <td>F</td> </tr> <tr> <td>hydrocortisone/pramoxine foam (Proctofoam-HC® – Salix Pharmaceuticals)</td> <td>F</td> </tr> <tr> <td>hydrocortisone suppository (Anucort-HC® – Salix Pharmaceuticals)</td> <td>NF</td> </tr> <tr> <td>hydrocortisone suppository (Proctocort® – Salix Pharmaceuticals)</td> <td>NF</td> </tr> <tr> <td>hydrocortisone suppository (generics)</td> <td>NF</td> </tr> </table>	budesonide rectal foam (Uceris® – Salix Pharmaceuticals)	NF	hydrocortisone retention enema (Colocort® – Dynamic Pharmaceuticals)	NF	hydrocortisone retention enema (generics)	F	hydrocortisone 2.5% cream (generics)	NF	hydrocortisone 2.5% cream (Procto-Med HC – Leading Pharmaceuticals)	NF	hydrocortisone 1% cream (Procto-Pak – Rising Pharmaceuticals)	F	hydrocortisone 2.5% cream (Proctosol HC – Taro Pharmaceuticals)	NF	hydrocortisone 2.5% cream (Proctozone HC – Rising Pharmaceuticals)	F	hydrocortisone 2.5% cream (Anusol-HC® – Salix Pharmaceuticals)	NF	hydrocortisone foam (Cortifoam® – Meda Pharmaceuticals)	F	hydrocortisone/pramoxine foam (Proctofoam-HC® – Salix Pharmaceuticals)	F	hydrocortisone suppository (Anucort-HC® – Salix Pharmaceuticals)	NF	hydrocortisone suppository (Proctocort® – Salix Pharmaceuticals)	NF	hydrocortisone suppository (generics)	NF		<p>(hydrocortisone 100mg/60mL enema) to formulary.</p> <p>Move Cortifoam to Non-formulary. Move Budesonide foam –Uceris to formulary with PA for trial/failure of proctofoam.</p> <p>Retain all other medications in current formulary status.</p> <p><b>Decision: Approved</b></p>
budesonide rectal foam (Uceris® – Salix Pharmaceuticals)	NF																														
hydrocortisone retention enema (Colocort® – Dynamic Pharmaceuticals)	NF																														
hydrocortisone retention enema (generics)	F																														
hydrocortisone 2.5% cream (generics)	NF																														
hydrocortisone 2.5% cream (Procto-Med HC – Leading Pharmaceuticals)	NF																														
hydrocortisone 1% cream (Procto-Pak – Rising Pharmaceuticals)	F																														
hydrocortisone 2.5% cream (Proctosol HC – Taro Pharmaceuticals)	NF																														
hydrocortisone 2.5% cream (Proctozone HC – Rising Pharmaceuticals)	F																														
hydrocortisone 2.5% cream (Anusol-HC® – Salix Pharmaceuticals)	NF																														
hydrocortisone foam (Cortifoam® – Meda Pharmaceuticals)	F																														
hydrocortisone/pramoxine foam (Proctofoam-HC® – Salix Pharmaceuticals)	F																														
hydrocortisone suppository (Anucort-HC® – Salix Pharmaceuticals)	NF																														
hydrocortisone suppository (Proctocort® – Salix Pharmaceuticals)	NF																														
hydrocortisone suppository (generics)	NF																														
	<p><b>Platelet Aggregation Inhibitors</b></p> <table border="1"> <thead> <tr> <th>Drug Name</th> <th>Current Formulary Status</th> </tr> </thead> <tbody> <tr> <td>Aggrenox® tablets (aspirin-dipyridamole) – Boehringer Ing.</td> <td>NF</td> </tr> <tr> <td>aspirin-dipyridamole tablets – generics</td> <td>F</td> </tr> <tr> <td>Brilinta® 60 mg tablets (ticagrelor) – Astrazeneca</td> <td>NF</td> </tr> </tbody> </table>	Drug Name	Current Formulary Status	Aggrenox® tablets (aspirin-dipyridamole) – Boehringer Ing.	NF	aspirin-dipyridamole tablets – generics	F	Brilinta® 60 mg tablets (ticagrelor) – Astrazeneca	NF		<p><b>Recommendation</b></p> <p><b>1.Change Brilinta 60 mg and 90 mg to Formulary with Step for trial of clopidogrel</b></p> <p><b>2.Change Effient to Formulary with step for trial of clopidogrel</b></p>																				
Drug Name	Current Formulary Status																														
Aggrenox® tablets (aspirin-dipyridamole) – Boehringer Ing.	NF																														
aspirin-dipyridamole tablets – generics	F																														
Brilinta® 60 mg tablets (ticagrelor) – Astrazeneca	NF																														

	<table border="1"> <tr> <td><b>Brilinta<sup>®</sup> 90 mg tablets (ticagrelor) – AstraZeneca</b></td> <td><b>F (PA)</b></td> </tr> <tr> <td><b>cilostazol tablets – generics</b></td> <td><b>F</b></td> </tr> <tr> <td><b>clopidogrel tablets – generics</b></td> <td><b>F</b></td> </tr> <tr> <td><b>Effient<sup>®</sup> tablets (prasugrel) – Eli Lilly &amp; Co.</b></td> <td><b>F (PA)</b></td> </tr> <tr> <td><b>pentoxifylline tablets – generics</b></td> <td><b>F</b></td> </tr> </table>	<b>Brilinta<sup>®</sup> 90 mg tablets (ticagrelor) – AstraZeneca</b>	<b>F (PA)</b>	<b>cilostazol tablets – generics</b>	<b>F</b>	<b>clopidogrel tablets – generics</b>	<b>F</b>	<b>Effient<sup>®</sup> tablets (prasugrel) – Eli Lilly &amp; Co.</b>	<b>F (PA)</b>	<b>pentoxifylline tablets – generics</b>	<b>F</b>			<p><b>3.Keep the current formulary status for the remaining drugs</b></p> <p><b>Decision: Approved</b></p>
<b>Brilinta<sup>®</sup> 90 mg tablets (ticagrelor) – AstraZeneca</b>	<b>F (PA)</b>													
<b>cilostazol tablets – generics</b>	<b>F</b>													
<b>clopidogrel tablets – generics</b>	<b>F</b>													
<b>Effient<sup>®</sup> tablets (prasugrel) – Eli Lilly &amp; Co.</b>	<b>F (PA)</b>													
<b>pentoxifylline tablets – generics</b>	<b>F</b>													
	<p><b>Low Molecular Weight Heparins</b></p> <table border="1"> <thead> <tr> <th><b>Drug Name</b></th> <th><b>Current Formulary Status</b></th> </tr> </thead> <tbody> <tr> <td><b>Enoxaparin injection – generics</b></td> <td><b>F</b></td> </tr> <tr> <td><b>Fondaparinux injection - generics</b></td> <td><b>F (PA)</b></td> </tr> <tr> <td><b>Fragmin<sup>®</sup> injection (dalteparin) – Pfizer</b></td> <td><b>NF</b></td> </tr> </tbody> </table>		<b>Drug Name</b>	<b>Current Formulary Status</b>	<b>Enoxaparin injection – generics</b>	<b>F</b>	<b>Fondaparinux injection - generics</b>	<b>F (PA)</b>	<b>Fragmin<sup>®</sup> injection (dalteparin) – Pfizer</b>	<b>NF</b>	<p><b>Recommendation</b></p> <p><b>1.Keep the current formulary status for the remaining drugs</b></p> <p><b>Decision: Approved</b></p>			
<b>Drug Name</b>	<b>Current Formulary Status</b>													
<b>Enoxaparin injection – generics</b>	<b>F</b>													
<b>Fondaparinux injection - generics</b>	<b>F (PA)</b>													
<b>Fragmin<sup>®</sup> injection (dalteparin) – Pfizer</b>	<b>NF</b>													
	<p><b>Oral Anticoagulants</b></p> <table border="1"> <thead> <tr> <th><b>Drug Name</b></th> <th><b>Current Formulary Status</b></th> </tr> </thead> <tbody> <tr> <td><b>Eliquis<sup>®</sup> tablets (apixaban) – Bristol-Myers Squibb/Pfizer</b></td> <td><b>F</b></td> </tr> <tr> <td><b>Pradaxa<sup>®</sup> capsules (dabigatran) – Boehringer Ing.</b></td> <td><b>F (PA)</b></td> </tr> <tr> <td><b>Xarelto<sup>®</sup> tablets (rivaroxaban) – Janssen</b></td> <td><b>F</b></td> </tr> <tr> <td><b>Coumadin<sup>®</sup> tablets (warfarin) – Bristol-</b></td> <td><b>NF</b></td> </tr> </tbody> </table>		<b>Drug Name</b>	<b>Current Formulary Status</b>	<b>Eliquis<sup>®</sup> tablets (apixaban) – Bristol-Myers Squibb/Pfizer</b>	<b>F</b>	<b>Pradaxa<sup>®</sup> capsules (dabigatran) – Boehringer Ing.</b>	<b>F (PA)</b>	<b>Xarelto<sup>®</sup> tablets (rivaroxaban) – Janssen</b>	<b>F</b>	<b>Coumadin<sup>®</sup> tablets (warfarin) – Bristol-</b>	<b>NF</b>	<p><b>Recommendation</b></p> <p>1. Move Jantoven to Formulary.</p> <p>2. Keep the current formulary status for all other agents</p> <p><b>Decision: Approved</b></p>	
<b>Drug Name</b>	<b>Current Formulary Status</b>													
<b>Eliquis<sup>®</sup> tablets (apixaban) – Bristol-Myers Squibb/Pfizer</b>	<b>F</b>													
<b>Pradaxa<sup>®</sup> capsules (dabigatran) – Boehringer Ing.</b>	<b>F (PA)</b>													
<b>Xarelto<sup>®</sup> tablets (rivaroxaban) – Janssen</b>	<b>F</b>													
<b>Coumadin<sup>®</sup> tablets (warfarin) – Bristol-</b>	<b>NF</b>													

	<table border="1"> <tr> <td><b>Myers Squibb</b></td> <td></td> </tr> <tr> <td><b>Jantoven<sup>®</sup> tablets (warfarin) – Upsher Smith</b></td> <td><b>NF</b></td> </tr> <tr> <td><b>warfarin tablets – generics</b></td> <td><b>F</b></td> </tr> <tr> <td><b>Savaysa<sup>™</sup> tablets (edoxaban) – Daiichi Sankyo</b></td> <td><b>NF</b></td> </tr> </table>	<b>Myers Squibb</b>		<b>Jantoven<sup>®</sup> tablets (warfarin) – Upsher Smith</b>	<b>NF</b>	<b>warfarin tablets – generics</b>	<b>F</b>	<b>Savaysa<sup>™</sup> tablets (edoxaban) – Daiichi Sankyo</b>	<b>NF</b>																																	
<b>Myers Squibb</b>																																										
<b>Jantoven<sup>®</sup> tablets (warfarin) – Upsher Smith</b>	<b>NF</b>																																									
<b>warfarin tablets – generics</b>	<b>F</b>																																									
<b>Savaysa<sup>™</sup> tablets (edoxaban) – Daiichi Sankyo</b>	<b>NF</b>																																									
	<table border="1"> <tr> <td colspan="3"><b>Antiretrovirals</b></td> <td rowspan="15"> <b>Recommendation</b>   1. Retain all current formulary status for all ARVs   <b>Decision:</b>  <b>Approved</b> </td> </tr> <tr> <td><b>Therapeutic Class</b></td> <td><b>Drug Name</b></td> <td><b>Current Formulary Status</b></td> </tr> <tr> <td rowspan="8"><b>Protease Inhibitors</b></td> <td>atazanavir (Reyataz<sup>®</sup> – Bristol-Myers-Squibb)</td> <td>F</td> </tr> <tr> <td>darunavir (Prezista<sup>®</sup> – Tibotec)</td> <td>F</td> </tr> <tr> <td>fosamprenavir (Lexiva<sup>®</sup> – GlaxoSmithKline)</td> <td>F</td> </tr> <tr> <td>indinavir (Crixivan<sup>®</sup> – Merck)</td> <td>F</td> </tr> <tr> <td>nelfinavir (Viracept<sup>®</sup> – Pfizer)</td> <td>F</td> </tr> <tr> <td>ritonavir (Norvir<sup>®</sup> – Abbott)</td> <td>F</td> </tr> <tr> <td>saquinavir (Invirase<sup>®</sup> – Roche)</td> <td>F</td> </tr> <tr> <td>tipranavir (Aptivus<sup>®</sup> – Boehringer-Ingelheim)</td> <td>F</td> </tr> <tr> <td rowspan="3"><b>Protease Inhibitor Combinations</b></td> <td>lopinavir/ritonavir (Kaletra<sup>®</sup> – Abbott)</td> <td>F</td> </tr> <tr> <td>Darunavir/cobicistat (Prezcobix<sup>®</sup> – Janssen)</td> <td>F</td> </tr> <tr> <td>Atazanavir/cobicistat (Evotaz<sup>®</sup> – Bristol-Myers Squibb)</td> <td>F</td> </tr> <tr> <td><b>Nucleotide Analog Reverse Transcriptase Inhibitor</b></td> <td>tenofovir (Viread<sup>®</sup> – Gilead)</td> <td>F</td> </tr> <tr> <td rowspan="3"><b>Nucleoside Reverse Transcriptase Inhibitors</b></td> <td>abacavir (Ziagen<sup>®</sup> – GlaxoSmithKline)</td> <td>F</td> </tr> <tr> <td>didanosine (Videx<sup>®</sup> pediatric solution – Bristol-Myers-Squibb)</td> <td>F</td> </tr> <tr> <td>didanosine delayed-release (generics)</td> <td>F</td> </tr> </table>	<b>Antiretrovirals</b>			<b>Recommendation</b>  1. Retain all current formulary status for all ARVs  <b>Decision:</b> <b>Approved</b>	<b>Therapeutic Class</b>	<b>Drug Name</b>	<b>Current Formulary Status</b>	<b>Protease Inhibitors</b>	atazanavir (Reyataz <sup>®</sup> – Bristol-Myers-Squibb)	F	darunavir (Prezista <sup>®</sup> – Tibotec)	F	fosamprenavir (Lexiva <sup>®</sup> – GlaxoSmithKline)	F	indinavir (Crixivan <sup>®</sup> – Merck)	F	nelfinavir (Viracept <sup>®</sup> – Pfizer)	F	ritonavir (Norvir <sup>®</sup> – Abbott)	F	saquinavir (Invirase <sup>®</sup> – Roche)	F	tipranavir (Aptivus <sup>®</sup> – Boehringer-Ingelheim)	F	<b>Protease Inhibitor Combinations</b>	lopinavir/ritonavir (Kaletra <sup>®</sup> – Abbott)	F	Darunavir/cobicistat (Prezcobix <sup>®</sup> – Janssen)	F	Atazanavir/cobicistat (Evotaz <sup>®</sup> – Bristol-Myers Squibb)	F	<b>Nucleotide Analog Reverse Transcriptase Inhibitor</b>	tenofovir (Viread <sup>®</sup> – Gilead)	F	<b>Nucleoside Reverse Transcriptase Inhibitors</b>	abacavir (Ziagen <sup>®</sup> – GlaxoSmithKline)	F	didanosine (Videx <sup>®</sup> pediatric solution – Bristol-Myers-Squibb)	F	didanosine delayed-release (generics)	F
<b>Antiretrovirals</b>			<b>Recommendation</b>  1. Retain all current formulary status for all ARVs  <b>Decision:</b> <b>Approved</b>																																							
<b>Therapeutic Class</b>	<b>Drug Name</b>	<b>Current Formulary Status</b>																																								
<b>Protease Inhibitors</b>	atazanavir (Reyataz <sup>®</sup> – Bristol-Myers-Squibb)	F																																								
	darunavir (Prezista <sup>®</sup> – Tibotec)	F																																								
	fosamprenavir (Lexiva <sup>®</sup> – GlaxoSmithKline)	F																																								
	indinavir (Crixivan <sup>®</sup> – Merck)	F																																								
	nelfinavir (Viracept <sup>®</sup> – Pfizer)	F																																								
	ritonavir (Norvir <sup>®</sup> – Abbott)	F																																								
	saquinavir (Invirase <sup>®</sup> – Roche)	F																																								
	tipranavir (Aptivus <sup>®</sup> – Boehringer-Ingelheim)	F																																								
<b>Protease Inhibitor Combinations</b>	lopinavir/ritonavir (Kaletra <sup>®</sup> – Abbott)	F																																								
	Darunavir/cobicistat (Prezcobix <sup>®</sup> – Janssen)	F																																								
	Atazanavir/cobicistat (Evotaz <sup>®</sup> – Bristol-Myers Squibb)	F																																								
<b>Nucleotide Analog Reverse Transcriptase Inhibitor</b>	tenofovir (Viread <sup>®</sup> – Gilead)	F																																								
<b>Nucleoside Reverse Transcriptase Inhibitors</b>	abacavir (Ziagen <sup>®</sup> – GlaxoSmithKline)	F																																								
	didanosine (Videx <sup>®</sup> pediatric solution – Bristol-Myers-Squibb)	F																																								
	didanosine delayed-release (generics)	F																																								



		emtricitabine (Emtriva® – Gilead)	F	
		lamivudine (Epivir® – GlaxoSmithKline)	F	
		stavudine (Zerit® – Bristol-Myers-Squibb)	F	
		zidovudine (generics)	F	
	<b>Nucleoside Analog Reverse Transcriptase Inhibitor Combinations</b>	abacavir/lamivudine (Epzicom® – GlaxoSmithKline)	F	
		abacavir/lamivudine/zidovudine (Trizivir® – GlaxoSmithKline)	F	
		abacavir/lamivudine/dolutegravir (Triumeq® – GlaxoSmithKline)	F	
		emtricitabine/efavirenz/tenofovir (Atripla® – Gilead)	F	
		emtricitabine/rilpivirine/tenofovir (Complera® – Gilead)	F	
		emtricitabine/rilpivirine/tenofovir (Odefsey® – Gilead)		
		emtricitabine/tenofovir (Truvada® – Gilead)	F	
		lamivudine/zidovudine (Combivir® – GlaxoSmithKline)	F	
		emtricitabine/tenofovir alafenamide (Descovy® –	F	
		Cobicistat/elvitegravir/emtricitabine/tenofovir (Stribild® –	F	
		Cobicistat/elvitegravir/emtricitabine/tenofovir (Genvoya® –	F	
		delavirdine (Rescriptor® – Pfizer)	F	
		<b>Non-Nucleoside Reverse Transcriptase Inhibitors</b>	efavirenz (Sustiva® – Bristol-Myers-Squibb)	F
	etravirine (Intelence® – Tibotec Therapeutics)		F	
	nevirapine (generic)		F	
	nevirapine enteric coated (generic)		F	
	rilpivirine (Edurant® – Tibotec Therapeutics)		F	
	enfuvirtide (Fuzeon® – Roche)		F	
	<b>Fusion Inhibitors</b>	raltegravir (Isentress® – Merck)	F	
	<b>Integrase Inhibitors</b>	elvitegravir (Vitekta® – Gilead)	F	

		dolutegravir (Tivicay <sup>®</sup> – ViiV Healthcare/GlaxoSmithKline)	F																	
	CCR5 Antagonist	maraviroc (Selzentry <sup>®</sup> – Pfizer)	F																	
	CYP3A Inhibitor (Booster agent- no antiretroviral activity)	cobicistat (Tybost <sup>®</sup> – Gilead)	F																	
	<b>Antiherpetics</b>			<b>Recommendation</b>																
	<table border="1"> <thead> <tr> <th>Drug Name</th> <th>Current Formulary Status</th> </tr> </thead> <tbody> <tr> <td>acyclovir oral tablet (generic)</td> <td>F</td> </tr> <tr> <td>acyclovir buccal (Sitavig<sup>®</sup> – Cipher Pharmaceuticals)</td> <td>NF</td> </tr> <tr> <td>acyclovir topical (generic)</td> <td>F</td> </tr> <tr> <td>acyclovir/hydrocortisone topical (Xerese<sup>™</sup> – Valeant)</td> <td>NF</td> </tr> <tr> <td>famciclovir tablet (generic)</td> <td>F [PA]</td> </tr> <tr> <td>penciclovir topical (Denavir<sup>®</sup> – Prestium Pharma)</td> <td>NF</td> </tr> <tr> <td>valacyclovir tablet (generic)</td> <td>F</td> </tr> </tbody> </table>		Drug Name	Current Formulary Status	acyclovir oral tablet (generic)	F	acyclovir buccal (Sitavig <sup>®</sup> – Cipher Pharmaceuticals)	NF	acyclovir topical (generic)	F	acyclovir/hydrocortisone topical (Xerese <sup>™</sup> – Valeant)	NF	famciclovir tablet (generic)	F [PA]	penciclovir topical (Denavir <sup>®</sup> – Prestium Pharma)	NF	valacyclovir tablet (generic)	F		1. Retain all current formulary status for all topical antiherpetics.  <b>Decision: Approved</b>
Drug Name	Current Formulary Status																			
acyclovir oral tablet (generic)	F																			
acyclovir buccal (Sitavig <sup>®</sup> – Cipher Pharmaceuticals)	NF																			
acyclovir topical (generic)	F																			
acyclovir/hydrocortisone topical (Xerese <sup>™</sup> – Valeant)	NF																			
famciclovir tablet (generic)	F [PA]																			
penciclovir topical (Denavir <sup>®</sup> – Prestium Pharma)	NF																			
valacyclovir tablet (generic)	F																			
	<b>Influenza</b>			<b>Recommendation</b>																
	<table border="1"> <thead> <tr> <th>Drug Name</th> <th>Current Formulary Status</th> </tr> </thead> <tbody> </tbody> </table>		Drug Name	Current Formulary Status		1. Retain all current														
Drug Name	Current Formulary Status																			

	<table border="1"> <tr><td>amantadine capsule (generic)</td><td>F</td></tr> <tr><td>amantadine solution (generic)</td><td>F</td></tr> <tr><td>amantadine tablet (generic)</td><td>F</td></tr> <tr><td>oseltamivir (Tamiflu® – Genentech)</td><td>F</td></tr> <tr><td>rimantadine (Flumadine® – Forest Pharmaceuticals)</td><td>NF</td></tr> <tr><td>zanamavir (Relenza® Diskhaler – GlaxoSmithKline)</td><td>F</td></tr> </table>	amantadine capsule (generic)	F	amantadine solution (generic)	F	amantadine tablet (generic)	F	oseltamivir (Tamiflu® – Genentech)	F	rimantadine (Flumadine® – Forest Pharmaceuticals)	NF	zanamavir (Relenza® Diskhaler – GlaxoSmithKline)	F		<p>formulary status for all influenza medications.</p> <p><b>Decision:</b> Approved</p>																
amantadine capsule (generic)	F																														
amantadine solution (generic)	F																														
amantadine tablet (generic)	F																														
oseltamivir (Tamiflu® – Genentech)	F																														
rimantadine (Flumadine® – Forest Pharmaceuticals)	NF																														
zanamavir (Relenza® Diskhaler – GlaxoSmithKline)	F																														
	<p><b>Antifungal Agents</b></p> <table border="1"> <thead> <tr> <th>Drug Name</th> <th>Current Formulary Status</th> </tr> </thead> <tbody> <tr><td>butenafine 1% cream (Mentax® – Mylan)</td><td>F</td></tr> <tr><td>ciclopirox topical (generics)</td><td>F</td></tr> <tr><td>ciclopirox olamine (generics)</td><td>F</td></tr> <tr><td>clotrimazole oral (generics)</td><td>F</td></tr> <tr><td>clotrimazole topical (generics)</td><td>F</td></tr> <tr><td>clotrimazole vaginal (generics)</td><td>F</td></tr> <tr><td>clotrimazole /betamethasone</td><td>F</td></tr> <tr><td>econazole nitrate topical (generics)</td><td>F</td></tr> <tr><td>efinaconazole (Jublia® – Valeant)</td><td>NF</td></tr> <tr><td>fluconazole oral (generics)</td><td>F</td></tr> <tr><td>griseofulvin microsize oral (generics)</td><td>F</td></tr> <tr><td>griseofulvin ultramicrosize oral (Gris-PEG® – Pedinol)</td><td>F</td></tr> <tr><td>itraconazole oral (generics)</td><td>F [PA]</td></tr> </tbody> </table>	Drug Name	Current Formulary Status	butenafine 1% cream (Mentax® – Mylan)	F	ciclopirox topical (generics)	F	ciclopirox olamine (generics)	F	clotrimazole oral (generics)	F	clotrimazole topical (generics)	F	clotrimazole vaginal (generics)	F	clotrimazole /betamethasone	F	econazole nitrate topical (generics)	F	efinaconazole (Jublia® – Valeant)	NF	fluconazole oral (generics)	F	griseofulvin microsize oral (generics)	F	griseofulvin ultramicrosize oral (Gris-PEG® – Pedinol)	F	itraconazole oral (generics)	F [PA]		<p><b>Recommendation</b></p> <p>1)Move nystatin/triamcinolone combination cream and ointment to non-formulary. Must use single agents</p> <p>2)Add Step criteria (trial and failure of azole) to naftinide (generic) topical</p> <p>3)Keep Jublia® and Kerytin® as non-formulary and add coverage criteria</p> <p><b>Decision:</b></p>
Drug Name	Current Formulary Status																														
butenafine 1% cream (Mentax® – Mylan)	F																														
ciclopirox topical (generics)	F																														
ciclopirox olamine (generics)	F																														
clotrimazole oral (generics)	F																														
clotrimazole topical (generics)	F																														
clotrimazole vaginal (generics)	F																														
clotrimazole /betamethasone	F																														
econazole nitrate topical (generics)	F																														
efinaconazole (Jublia® – Valeant)	NF																														
fluconazole oral (generics)	F																														
griseofulvin microsize oral (generics)	F																														
griseofulvin ultramicrosize oral (Gris-PEG® – Pedinol)	F																														
itraconazole oral (generics)	F [PA]																														

	itraconazole oral (Onmel® – Merz)	NF	Approved
	ketoconazole oral (generics)	F	
	ketoconazole cream (generics)	F	
	ketoconazole shampoo	F	
	ketoconazole foam (Extina® – Stiefel, generic)	NF	
	luliconazole topical (Luzu® – Medicis)	NF	
	miconazole topical (generic, Baza® – Coloplast, Remedy® – Medline, Secura™ – Smith & Nephew)	F	
	naftifine cream (generics)	F	
	naftifine gel (Naftin® – Merz Pharmaceuticals)	F	
	nystatin topical (generics)	F	
	nystatin/triamcinolone topical (generics)	F	
	oxiconazole nitrate topical (generics)	NF	
	posaconazole oral (Noxafil® – Merck)	F [PA]	
	sertaconazole topical (Ertaczo® – Valeant)	NF	
	sulconazole topical (Exelderm® – Ranbaxy)	NF	
	tavaborole topical (Kerydin® – Anacor)	NF	
	terbinafine oral (Lamisil AT®)	NF	
	terbinafine oral (generics)	F	
	terbinafine topical (generics)	F	
	tolnaftate topical (generics)	F	
	tolnaftate topical (Lamisil AF®, Tinactin® – Bayer)	NF	
	voriconazole oral (generics)	F	
	voriconazole oral suspension (generics)	NF	

	<p><b>Oral Hepatitis B Agents</b></p> <table border="1"> <thead> <tr> <th data-bbox="396 350 1047 461">Drug Name</th> <th data-bbox="1047 350 1304 461">Current Formulary Status</th> </tr> </thead> <tbody> <tr> <td data-bbox="396 461 1047 537">adefovir tablets (Hepsera<sup>®</sup> – Gilead Sciences, generics)</td> <td data-bbox="1047 461 1304 537">F [PA]</td> </tr> <tr> <td data-bbox="396 537 1047 613">entecavir (Baraclude<sup>®</sup> – Bristol-Myers Squibb, generics tablets only)</td> <td data-bbox="1047 537 1304 613">F</td> </tr> <tr> <td data-bbox="396 613 1047 721">lamivudine oral solution and tablets (Epivir HBV<sup>®</sup> – GlaxoSmithKline, generics tablets only)</td> <td data-bbox="1047 613 1304 721">F</td> </tr> <tr> <td data-bbox="396 721 1047 797">telbivudine oral solution and tablets (Tyzeka<sup>®</sup> – Novartis)</td> <td data-bbox="1047 721 1304 797">F [PA]</td> </tr> <tr> <td data-bbox="396 797 1047 873">tenofovir tablets and powder (Viread<sup>®</sup> – Gilead Sciences)</td> <td data-bbox="1047 797 1304 873">F</td> </tr> </tbody> </table>	Drug Name	Current Formulary Status	adefovir tablets (Hepsera <sup>®</sup> – Gilead Sciences, generics)	F [PA]	entecavir (Baraclude <sup>®</sup> – Bristol-Myers Squibb, generics tablets only)	F	lamivudine oral solution and tablets (Epivir HBV <sup>®</sup> – GlaxoSmithKline, generics tablets only)	F	telbivudine oral solution and tablets (Tyzeka <sup>®</sup> – Novartis)	F [PA]	tenofovir tablets and powder (Viread <sup>®</sup> – Gilead Sciences)	F	<p><b>Recommendation</b></p> <p>1.Retain the current formulary status for all Hepatitis B oral agents</p> <p><b>Decision Approved</b></p>
Drug Name	Current Formulary Status													
adefovir tablets (Hepsera <sup>®</sup> – Gilead Sciences, generics)	F [PA]													
entecavir (Baraclude <sup>®</sup> – Bristol-Myers Squibb, generics tablets only)	F													
lamivudine oral solution and tablets (Epivir HBV <sup>®</sup> – GlaxoSmithKline, generics tablets only)	F													
telbivudine oral solution and tablets (Tyzeka <sup>®</sup> – Novartis)	F [PA]													
tenofovir tablets and powder (Viread <sup>®</sup> – Gilead Sciences)	F													
	<p><b>Macrolides and Ketolides</b></p> <table border="1"> <thead> <tr> <th data-bbox="396 1013 1018 1089">Drug Name</th> <th data-bbox="1018 1013 1293 1089">Current Formulary Status</th> </tr> </thead> <tbody> <tr> <td data-bbox="396 1089 1018 1166">azithromycin tablets and oral suspension (generic)</td> <td data-bbox="1018 1089 1293 1166">F</td> </tr> <tr> <td data-bbox="396 1166 1018 1203">azithromycin tablets (Zithromax<sup>®</sup> – Pfizer)</td> <td data-bbox="1018 1166 1293 1203">NF</td> </tr> <tr> <td data-bbox="396 1203 1018 1279">clarithromycin tablets and oral suspension (generics)</td> <td data-bbox="1018 1203 1293 1279">F</td> </tr> <tr> <td data-bbox="396 1279 1018 1356">clarithromycin extended-release tablets (Biaxin<sup>®</sup> XL – Abbott; generics)</td> <td data-bbox="1018 1279 1293 1356">NF</td> </tr> </tbody> </table>	Drug Name	Current Formulary Status	azithromycin tablets and oral suspension (generic)	F	azithromycin tablets (Zithromax <sup>®</sup> – Pfizer)	NF	clarithromycin tablets and oral suspension (generics)	F	clarithromycin extended-release tablets (Biaxin <sup>®</sup> XL – Abbott; generics)	NF	<p><b>Recommendation</b></p> <p>1.Retain all medications in current formulary status.</p> <p><b>Decision: Approved</b></p>		
Drug Name	Current Formulary Status													
azithromycin tablets and oral suspension (generic)	F													
azithromycin tablets (Zithromax <sup>®</sup> – Pfizer)	NF													
clarithromycin tablets and oral suspension (generics)	F													
clarithromycin extended-release tablets (Biaxin <sup>®</sup> XL – Abbott; generics)	NF													

	erythromycin base 250mg delayed-release capsules (generics)	F		
	erythromycin base 333mg delayed-release tablets (generics)	F		
	erythromycin base 250mg tablets (generics)	F		
	erythromycin base 500mg tablets (generics)	F		
	Ery-tab <sup>®</sup> delayed release (erythromycin – Arbor Pharmaceuticals)	F		
	erythromycin ethylsuccinate 400mg tablet (generics)	F		
	E.E.S granules <sup>®</sup> for reconstitution (erythromycin- Arbor Pharmaceuticals)	NF		
	Eryped <sup>®</sup> 200 suspension (Abbott)	NF		
	Eryped <sup>®</sup> 400 suspension (Abbott)	NF		
	erythromycin ethylsuccinate oral suspension (generics)	F		
	fidaxomicin tablets (Difcid <sup>®</sup> , Dificlir <sup>®</sup> ; Optimir Pharmaceuticals)	F		
	telithromycin tablets (Ketek <sup>®</sup> – Sanofi-Aventis; generics)	F [PA]		
	<b>Beta-Lactam Antibiotics</b>			<b>Recommendation</b>
				1.Retain current formulary status for all beta-lactam antibiotics.
	<b>Drug Name</b>	<b>Current Formulary Status</b>		
	amoxicillin extended-release (Moxatag <sup>®</sup> – Shionogi Pharma)	NF		<b>Decision:</b>
	amoxicillin capsule, tablet, chewable,	F		<b>Approved</b>

<b>suspension – generics</b>			
<b>amoxicillin/clavulanate - generics [Augmentin<sup>®</sup>]</b>	<b>F</b>		
<b>amoxicillin/clavulanate extended release (Augmentin<sup>®</sup> XR – GlaxoSmithKline)</b>	<b>NF</b>		
<b>amoxicillin/clavulanate suspension (generics)</b>	<b>F</b>		
<b>amoxicillin/clavulanate suspension (Augmentin<sup>®</sup> ES 600– Dr. Reddy’s Laboratories)</b>	<b>NF</b>		
<b>amoxicillin/clavulanate chewable (Augmentin<sup>®</sup> – Dr. Reddy’s Laboratories, generics)</b>	<b>F</b>		
<b>ampicillin capsule – generics</b>	<b>F</b>		
<b>cefaclor capsule - generics {2<sup>nd</sup>}</b>	<b>F</b>		
<b>cefaclor suspension {2<sup>nd</sup>}</b>	<b>NF</b>		
<b>cefaclor extended-release tablets {2<sup>nd</sup>}</b>	<b>NF</b>		
<b>cefadroxil capsule, tablets, and suspension – generics {1<sup>st</sup>}</b>	<b>F</b>		
<b>cefdinir capsules and suspension - generics [Omnicef<sup>®</sup>] {3<sup>rd</sup>}</b>	<b>F</b>		
<b>cefditoren pivoxil tablets (Spectracef<sup>®</sup> – Cornerstone BioPharma) {3<sup>rd</sup>}</b>	<b>NF</b>		
<b>cefixime suspension – generics {3<sup>rd</sup>}</b>	<b>F</b>		
<b>cefprozime proxetil tablets and suspension – generics {3<sup>rd</sup>}</b>	<b>F</b>		
<b>cefprozil tablets and suspension - generics {2<sup>nd</sup>}</b>	<b>F</b>		
<b>ceftibuten capsules and suspension (Cedax<sup>®</sup> – Shionogi USA) {3<sup>rd</sup>}</b>	<b>NF</b>		
<b>cefuroxime axetil tablets – generics {2<sup>nd</sup>}</b>	<b>F</b>		

	<b>cefuroxime axetil suspension (Ceftin<sup>®</sup> – GlaxoSmithKline) {2<sup>nd</sup>}</b>	<b>F</b>		
	<b>cephalexin capsules, tablets, and suspension – generics {1<sup>st</sup>}</b>	<b>F</b>		
	<b>dicloxacillin – generics</b>	<b>F</b>		
	<b>penicillin tablets and solution – generics</b>	<b>F</b>		
	<b>penicillin (Bicillin L-A<sup>®</sup> – Pfizer)</b>	<b>F</b>		